Why the study?
The study was conducted to determine the diagnostic and prognostic role of cystatin C in the development of cardiorenal syndrome in arterial hypertension with comorbid conditions.
Is cystatin C associated with the development of cardiorenal syndrome in patients with arterial hypertension and metabolic comorbidities?
Is cystatin C associated with the development of cardiorenal syndrome in patients with arterial hypertension and metabolic comorbidities?
Elevated cystatin C levels are associated with increased blood pressure and neurohumoral markers, suggesting a role in the early development of cardiorenal complications in hypertensive patients with metabolic comorbidities.
May flag early cardiorenal risk in comorbid hypertension; hypothesis-generating, requiring longitudinal studies before clinical use.
The purpose of our study was to determine of diagnostic and prognostic role of cystatin C in the development of cardiorenal syndrome in the case of arterial hypertension syndrome and maximum comorbid conditions. 111 patients and 20 persons of the control group were examined. In the current examination process, they were divided into 4 groups depending on the presence of comorbid pathology in them: patients with arterial hypertension – 1 group – 22 people; patientswith arterial hypertension in combination with obesity – group 2 – 30 people; arterial hypertension in combination with type 2 diabetes – group 3 – 31 people; patients with hypertension, type 2 diabetes and obesity – group 4 – 28 people. The level of cystatin C in the examined cases with arterial hypertension and various comorbidities was significantly higher compared to individuals of the control group. Significant effect of the cardiotrophin-1 residue on cystatin C. An increased level of cystatin C is associated with an increase in blood pressure, the level of cardiotrophin-1, catestatin, which ensures its role in the early development of nervous and cardiovascular complications in patients with arterial hypertension with various hormonal comorbidities and confirms the significance of the activity of adipose tissue in the development of kidney dysfunction.
No takes yet. Share an insight, caveat, or question.
Інна Дунаєва (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: